BMRN – biomarin pharmaceutical inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day BMRN SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
2/23/2026
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
-0.5%
10/27/2025
04:03 pm
bmrn
biomarin pharmaceutical inc.
MISS
1.6%
8/4/2025
04:02 pm
bmrn
biomarin pharmaceutical inc.
BEAT
2.7%
5/1/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
-1.1%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
5/14 Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES 7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
Top News Decliners
3/11 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES -12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BMRN
SPY
QQQ
SPX
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BMRN SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
4/17
06:05 pm
bmrn
Low
BioMarin Pharmaceutical (BMRN) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d+)".
4/15
01:03 pm
bmrn
Low
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha]
4/1
06:04 pm
bmrn
Medium
BioMarin Pharmaceutical (BMRN) was upgraded by Weiss Ratings from "sell (d+)" to "hold (c-)".
3/31
03:33 am
bmrn
Medium
Here is Why BioMarin (BMRN) is Projected to Rally [Yahoo! Finance]
3/30
07:26 am
bmrn
Low
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance]
3/26
05:49 am
bmrn
Low
BioMarin Pharmaceutical (BMRN) was upgraded by Truist Financial Corporation to "strong-buy".
3/20
02:28 pm
bmrn
Low
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]
3/18
08:39 pm
bmrn
Low
How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal [Yahoo! Finance]
3/17
09:03 am
bmrn
Low
BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]
2/23/2026
04:05 pm
bmrn
-0.5%
BEAT
10/27/2025
04:03 pm
bmrn
1.6%
MISS
8/4/2025
04:02 pm
bmrn
2.7%
BEAT
5/1/2025
04:05 pm
bmrn
-1.1%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
3/16
12:08 pm
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
3/16
12:08 pm
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
3/4
09:36 am
Maintains
Overweight
Overweight
Barclays
Low
2.7%
3/4
09:36 am
Maintains
Overweight
Overweight
Barclays
Low
2.7%
3/3
07:18 am
Reiterates
Overweight
Overweight
Barclays PLC
Low
-0.1%
2/26
02:51 pm
Maintains
Buy
Buy
Canaccord Genuity
Low
0.5%
2/25
11:59 am
Maintains
Outperform
Outperform
Bernstein
Low
-0.5%
2/25
11:59 am
Maintains
Outperform
Outperform
Bernstein
Low
-0.5%
2/25
09:18 am
Maintains
Buy
Buy
Guggenheim
Low
-1.5%
3/26
04:10 pm
bmrn
Low
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VANGUARD GROUP INC
3/19
04:53 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 18 Filed by: Davis George Eric
3/19
04:51 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Guyer Charles Greg
3/19
04:49 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Mueller Brian
3/19
04:34 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hardy Alexander
3/18
01:42 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Hubbard Cristin
3/18
01:40 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Friberg Gregory R
3/17
08:51 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Guyer Charles Greg
3/17
08:48 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Davis George Eric
Show more
Top News Gainers
5/14 Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES 7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
Top News Decliners
3/11 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES -12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%